4.8 Article

The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Medicine, General & Internal

Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure

Deepak L. Bhatt et al.

Summary: In patients with diabetes and recent worsening heart failure, treatment with sotagliflozin significantly reduced the total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure compared to placebo, regardless of the timing of administration.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Article Biochemistry & Molecular Biology

The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial

Michael E. Nassif et al.

Summary: In a randomized trial, the SGLT2 inhibitor dapagliflozin significantly improved the health status and exercise function of patients with heart failure with preserved ejection fraction (HFpEF) over a 12-week period, which can lead to an enhanced quality of life for these patients.

NATURE MEDICINE (2021)

Article Cardiac & Cardiovascular Systems

Novel Trial Design: CHIEF-HF

John A. Spertus et al.

Summary: This study describes a decentralized, patient-centered randomized clinical trial using mobile technologies to test the efficacy of canagliflozin for improving heart failure symptoms. The primary outcome is the change in the total symptom score of the Kansas City Cardiomyopathy Questionnaire over 12 weeks, with secondary outcomes including daily step count and other scales from the questionnaire.

CIRCULATION-HEART FAILURE (2021)

Article Medicine, General & Internal

Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease

W. S. Jones et al.

Summary: In a pragmatic trial involving patients with established cardiovascular disease, no significant differences were found in cardiovascular events or major bleeding between patients assigned to daily 81 mg and those assigned to 325 mg of aspirin.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Article Medicine, General & Internal

Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial

JoAnn Lindenfeld et al.

Summary: The study aimed to evaluate whether haemodynamic-guided management of heart failure is applicable to patients with different severity of symptoms (NYHA functional class II-IV). The overall study analysis showed that haemodynamic-guided management did not reduce the mortality rate and heart failure events in heart failure patients. However, a pre-COVID-19 impact analysis suggested a potential benefit of haemodynamic-guided management for heart failure patients, primarily by lowering the heart failure hospitalisation rate.

LANCET (2021)

News Item Medicine, General & Internal

Dapagliflozin Cut Risk of Worsening Heart Failure

Anita Slomski

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Editorial Material Cardiac & Cardiovascular Systems

Heart Failure Collaboratory Statement on Clinical Trials in the Landscape of COVID-19

William T. Abraham et al.

JACC-HEART FAILURE (2020)

Review Cardiac & Cardiovascular Systems

Interpreting the Kansas City Cardiomyopathy Questionnaire in Clinical Trials and Clinical Care JACC State-of-the-Art Review

John A. Spertus et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)

Editorial Material Medicine, General & Internal

New Guidelines for Statistical Reporting in the Journal

David Harrington et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Article Medicine, General & Internal

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

J. J. V. McMurray et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Review Cardiac & Cardiovascular Systems

The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors

Javed Butler et al.

EUROPEAN JOURNAL OF HEART FAILURE (2017)

Article Cardiac & Cardiovascular Systems

Efficient design of clinical trials and epidemiological research: is it possible?

Michael S. Lauer et al.

NATURE REVIEWS CARDIOLOGY (2017)

Article Cardiac & Cardiovascular Systems

Trends in Heart Failure Clinical Trials From 2001-2012

Ayman Samman Tahhan et al.

JOURNAL OF CARDIAC FAILURE (2016)

Article Health Care Sciences & Services

Quantifying clinical change: discrepancies between patients' and providers' perspectives

Rachel P. Dreyer et al.

QUALITY OF LIFE RESEARCH (2016)

Article Cardiac & Cardiovascular Systems

Development and Validation of a Short Version of the Kansas City Cardiomyopathy Questionnaire

John A. Spertus et al.

CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES (2015)

Review Cardiac & Cardiovascular Systems

Cardiovascular Drug Development

Christopher B. Fordyce et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2015)

Article Medicine, General & Internal

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Bernard Zinman et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Article Cardiac & Cardiovascular Systems

Development and Validation of a Short Version of the Kansas City Cardiomyopathy Questionnaire

John A. Spertus et al.

CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES (2015)

Editorial Material Medicine, General & Internal

Transforming Clinical Trials in Cardiovascular Disease Mission Critical for Health and Economic Well-being

Elliott M. Antman et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)

Article Cardiac & Cardiovascular Systems

Monitoring clinical changes in patients with heart failure: A comparison of methods

J Spertus et al.

AMERICAN HEART JOURNAL (2005)